Skip to main navigation Skip to main content

Page translation not available

This page is not available in the language that has been selected and will appear in English.

Search

Contact us

07 3737 4500

PO Box 3787

South Brisbane QLD 4101
Become a patient

Dr Yada Kanjanapan

MBBS, FRACP

  • Medical Oncologist
Become a patient Refer a patient
Canberra
02 5112 0200 02 9167 9004
admin.canberra@icon.team

Biography

Dr Yada Kanjanapan is committed to delivering evidence-based care in collaboration with her multidisciplinary team of surgical and radiation oncologists.

Dr Yada Kanjanapan is an experienced medical oncologist at Icon Cancer Centre Canberra and a senior staff specialist at The Canberra Hospital. She obtained a Bachelor of Medicine and Bachelor of Surgery (MBBS) from the University of Adelaide and completed specialist oncology training at Canberra Hospital and Peter MacCallum Cancer Centre in Melbourne. Dr Kanjanapan subsequently completed a two-year clinical research fellowship in drug development, melanoma, and gynaecological cancers at the Princess Margaret Cancer Centre in Toronto, Canada. She held a medical oncology position at Sydney’s Prince of Wales Hospital where she managed a wide range of solid tumour malignancies.

Since returning to her hometown of Canberra, Dr Kanjanapan has been active in research, serving as a principal investigator in numerous clinical trials for breast and gynaecological cancers. Her research interests include breast cancer, immunotherapy, and developmental therapeutics, with a strong publication record. In 2018, Dr Kanjanapan was a recipient of an American Society of Clinical Oncology (ASCO) Merit Award. She is also a clinical Senior Lecturer at the Australian National University, teaching and mentoring medical students in clinical skills and research.

Dr Kanjanapan’s clinical experience covers a broad range of solid tumour malignancies with subspecialty expertise in breast cancer, gynaecological cancers, and skin cancers, particularly melanoma.

Publications

  • Real-world analysis of breast cancer patients qualifying for adjuvant CDK4/6 inhibitors, Clinical Breast Cancer. Kanjanapan Y, Anderson, W, Smith M, Green J, Chalker E, Craft P.  Clinical Breast Cancer, 2024.

  • Response to COVID-19 vaccination in patients on cancer therapy: Analysis in a SARS-CoV-2-naïve population. Cavic G, Almonte A, Hicks M, Neeman T, Wang JW, Brew S, Choi PY, Cockburn I, Gardiner E, Yip D, Fahrer A, Kanjanapan Y. Asia-Pacific Journal of Clinical Oncology, 2024.

  • Impact of prior (neo)adjuvant trastuzumab exposure on the efficacy of HER2 targeted therapy for metastatic breast cancer. Y. Kanjanapan,  D. Tran, S.W. Lok, P.Gibbs, R. De Boer, B. Yeo, S. Greenberg, F. Barnett, L. Nott, G. Richardson, R. Wong, M. Nottage, I. Collins, J. Torres, J. Lombard, J. Johns, M. Harold & L. Malik. Breast Cancer Research and Treatment, 2020.

  • Hyperprogressive disease in early‐phase immunotherapy trials: Clinical predictors and association with immune‐related toxicities. Y. Kanjanapan, D. Day, L. Wang, H. Al‐Sawaihey, E. Abbas, A. Namini, L.L. Siu, A. Hansen, A.A. Razak, A. Spreafico, N. Leighl, A.M. Joshua, M.O. Butler, D. Hogg, M.A. Chappell, L. Soultani, K. Chow, S. Boujo & P.L. Bedard. Cancer, 2019; 125(8): 1341-1349.

  • Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials. Y. Kanjanapan, D. Day, M.O. Butler, L. Wang, A.M. Joshua, D. Hogg, N.B. Leighl, A.R. Abdul Razak, A. Hansen, S. Boujos, M. Chappell, K.Chow, B. Sherwin, L.A. Stayner, L. Soultani, A. Zambrana, L.L. Siu, L.Bedard & A. Spreafico. European Journal of Cancer; 2019; 107: 1-7.

  • Novel patterns of response under immunotherapy. Borcoman, Y. Kanjanapan, S. Champiat, S. Kato, V. Servois, R. Kurzrock, S. Goel, P. Bedard & C. Le Tourneau. Annals of Oncology, 2019; 30: 385-396.